helicobacter%20pylori%20infection
HELICOBACTER PYLORI INFECTION
Helicobacter pylori is a spiral-shaped gram-negative bacterium involved in the development of gastritis, duodenal and gastric ulcers, and gastric cancer.
Infection is strongly associated with the development of gastric epithelial and lymphoid malignancies.
Acute infection is mostly asymptomatic and is acquired through human-to-human contact via gastro-oral and fecal-oral routes.
Adaptability in gastric conditions and production of urease allow it to colonize the stomach.

Follow Up

Patient should be re-tested after a minimum of 4 weeks after treatment

  • It is advisable to confirm eradication of H pylori with a posttreatment UBT or a monoclonal stool test
    • Antisecretory drugs especially PPIs should be discontinued at least 1-2 weeks prior to posttest, while Bismuth compounds and antibiotics should be stopped at least 4 weeks prior to test 
  • Patients with either gastric ulcers or complicated duodenal ulcers should have a repeat endoscopy and biopsy, UBT, or stool antigen test to rule out malignancy
  • In patients with persistent H pylori infection, a culture and sensitivity may be done before retreatment, except when considering a Bismuth-based quadruple therapy
  • Serology is not used in determining treatment response
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago
The likelihood of restarting treatment with direct oral anticoagulants (DOACs) following gastrointestinal bleeding (GIB) appears to be low among older patients who require blood and intensive care, a study has shown. Furthermore, a history of venous thromboembolism and thienopyridine use are risk factors for subsequent thromboembolism and GIB, respectively.
16 Jun 2018
Older women consuming high levels of dietary fibre in the long term appear to have a lower risk of developing faecal incontinence, a study reports.
Pank Jit Sin, 12 Jun 2018
The common antimicrobial agent, triclosan, has been implicated in colonic inflammation and the disease development of colitis and colitis-associated colon cancer, reveals a study appearing in Science Translational Medicine. [doi:10.1126/scitranslmed.aan4116]